From November 9 to 11, 2026, ETAP-LAB will attend BIO-Europe Fall in Cologne, Germany, one of Europe’s leading events dedicated to partnerships in biotechnology, pharmaceuticals, and healthcare innovation.
On this occasion, Nicolas Violle, CEO of SYNCROSOME, will represent all ETAP-LAB’s activities through partnering meetings with pharmaceutical companies, biotechs, medtechs, and innovation stakeholders from across Europe and around the world.
Our objective is clear: to establish new collaborations and support companies seeking an experienced preclinical partner capable of generating robust, reproducible, and translational data to accelerate their development programs.
A trusted preclinical partner to secure and accelerate your drug pipeline.
BIO-Europe Fall 2026: A Must-Attend Event for Biotech and Pharma Partnerships
Every year, BIO-Europe brings together the decision-makers shaping the life sciences industry, including biotech and pharmaceutical executives, investors, business development leaders, R&D experts, and strategic partners.
The previous edition welcomed more than 6,500 participants from 3,500 companies and generated over 35,000 PartneringONE™ meetings. This unique format enables therapeutic innovators to quickly identify partners capable of accelerating the development of their projects. Explore the BIO-Europe agenda.
For ETAP-LAB, this participation is part of an international growth strategy aimed at strengthening our presence among innovative healthcare companies across Europe.
Why Meet ETAP-LAB at BIO-Europe Fall 2026?
Developing a drug candidate involves complex decisions and significant investments. Whether you are engaging with investors, key opinion leaders, or regulatory agencies, the quality of preclinical data is a critical success factor.
For more than 35 years, ETAP-LAB has supported pharmaceutical, biotechnology, and medtech companies in evaluating therapeutic innovations through recognized scientific expertise and high-quality standards.
We provide support in:
- Lead optimization and drug candidate selection;
- In vitro and in vivo preclinical efficacy studies;
- Proof-of-concept (PoC) studies;
- PK/PD evaluations;
- Non-regulatory safety pharmacology;
- Programs involving antibodies, biologics, cell therapies, medical devices, and nutraceuticals.
Our ambition is to help clients reduce risk, accelerate development timelines, and make critical decisions with greater confidence.
Translational Preclinical Expertise for Robust and Relevant Data
One of the key challenges of preclinical development is generating results that reliably predict clinical outcomes in humans.
At ETAP-LAB, our strength lies in a deeply translational approach combining:
- Innovative and validated preclinical models;
- Rigorous study protocols;
- Stringent quality control procedures;
- Expert biostatistical analyses;
- A strong focus on data reproducibility.
Our goal is to provide reliable and actionable data that support critical project milestones, including candidate validation, fundraising activities, regulatory discussions, and progression toward clinical development.
This approach has already enabled numerous pharmaceutical and biotechnology companies to advance their programs into clinical phases based on robust and meaningful preclinical evidence.
Four Therapeutic Areas of Expertise Within a Single Preclinical CRO
At BIO-Europe Fall 2026, Nicolas Violle will present ETAP-LAB’s full range of expertise through its four specialized teams:
- SYNCROSOME: supports therapeutic development programs through recognized expertise in cardiology and pulmonary arterial hypertension (PAH), leveraging predictive preclinical models to generate high-value translational data.
- BRAINXPLORE: provides advanced expertise for programs targeting central nervous system disorders, particularly Alzheimer’s disease, through both in vitro and in vivo approaches.
- SKINAXIS: develops preclinical solutions dedicated to dermatology, tissue repair, and wound healing.
- STROK@LLIANCE: offers unique ischemic stroke models to evaluate novel therapeutic approaches in an area with significant unmet medical needs.
More Than 35 Years of Experience Supporting Therapeutic Innovation
Over the years, ETAP-LAB has become a trusted partner for numerous life science companies:
- 35+ years of experience in preclinical research;
- More than 1,000 preclinical studies performed;
- Over 300 clients supported worldwide;
- Nearly 100 scientific publications and conference posters across our therapeutic fields;
- Recognized expertise in cardiology, neurology, dermatology, and neurovascular diseases.
These achievements reflect our commitment to delivering high-quality scientific results that meet the expectations of biotechnology companies, pharmaceutical organizations, and investors alike.
Schedule a Meeting with Nicolas Violle at BIO-Europe Fall 2026
Are you developing drug candidates including small molecules, antibodies, biologics, cell therapies, immunotherapies, medical devices (biomaterials, biomimetic technologies), or nutraceutical products?
Are you looking for an experienced preclinical CRO capable of generating robust, decision-enabling data to accelerate your development program?
Take advantage of BIO-Europe Fall 2026 to meet directly with Nicolas Violle and explore the solutions best suited to your needs.
Meetings will be held exclusively through the event’s PartneringONE™ platform. You may also contact our team directly through our contact form.
We look forward to discussing your projects and helping you address your preclinical development challenges.
Participation Supported by Eurobiomed and Région Sud
SYNCROSOME’s participation, representing all ETAP-LAB activities during BIO-Europe Fall 2026, is supported by Eurobiomed, the leading healthcare innovation cluster in Southern France, and Région Sud Provence-Alpes-Côte d’Azur, as part of their programs supporting the growth and international development of innovative healthcare companies.
This support helps strengthen the visibility of French expertise in preclinical research and promotes the development of new scientific and industrial collaborations across Europe.
